

4 July 2022

## **New biologic medications for the treatment of dermatological conditions**

How many patients were treated in May 2022 (or latest available month) by the dermatology department with the following drugs:

- Abrocitinib (Cibinqo): Not used
- Baricitinib (Olumiant): **<5**
- Bimekizumab (Bimzelx): **<5**
- Brodalumab (Kyntheum): **<5**
- Dupilumab (Dupixent): **94**
- Ixekizumab (Taltz): **50**
- Risankizumab (Skyrizi): **60**
- Guselkumab (Tremfya): **87**
- Secukinumab (Cosentyx): **39**
- Tildrakizumab (Ilumetri): **6**
- Tralokinumab (Adtralza): Not used
- Upadacitinib (Rinvoq): **6**
- Ustekinumab (Stelara): **82**

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.